For: | Guardigni V, Badia L, Conti M, Rinaldi M, Mancini R, Viale P, Verucchi G. Liver decompensation predicts ribavirin overexposure in hepatitis C virus patients treated with direct-acting antivirals. World J Hepatol 2017; 9(34): 1270-1277 [PMID: 29290908 DOI: 10.4254/wjh.v9.i34.1270] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v9/i34/1270.htm |
Number | Citing Articles |
1 |
Nicola Schiano Moriello, Biagio Pinchera, Ivan Gentile. Personalized care approaches to hepatitis C therapy: recent advances and future directions. Expert Review of Anti-infective Therapy 2024; 22(4): 139 doi: 10.1080/14787210.2024.2328336
|
2 |
Mukta Agrawal, Shailendra Saraf, Swarnlata Saraf, Upadhyayula Suryanarayana Murty, Sucheta Banerjee Kurundkar, Debjani Roy, Pankaj Joshi, Dhananjay Sable, Yogendra Kumar Choudhary, Prashant Kesharwani, Amit Alexander. In-line treatments and clinical initiatives to fight against COVID-19 outbreak. Respiratory Medicine 2022; 191: 106192 doi: 10.1016/j.rmed.2020.106192
|
3 |
Saman Zafar, Muhammad Sohail Arshad, Sameen Fatima, Amna Ali, Aliyah Zaman, Elshaimaa Sayed, Ming-Wei Chang, Zeeshan Ahmad. COVID-19: Current Developments and Further Opportunities in Drug Delivery and Therapeutics. Pharmaceutics 2020; 12(10): 945 doi: 10.3390/pharmaceutics12100945
|
4 |
Xinyi Jiang, Hyun Jin Song, Wei Wang, Linda Henry, Lindsey M Childs-Kean, Vincent Lo Re, Haesuk Park. The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders. Journal of Managed Care & Specialty Pharmacy 2021; 27(7): 873 doi: 10.18553/jmcp.2021.27.7.873
|